Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2008-06-17
2008-06-17
Haddad, Maher M. (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S144100, C424S154100, C424S155100, C530S387300, C530S388230, C530S388700, C530S391700
Reexamination Certificate
active
07387776
ABSTRACT:
Isolated human monoclonal antibodies which bind to CD30 (e.g., human CD30) are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
REFERENCES:
patent: 5165923 (1992-11-01), Thorpe et al.
patent: 5643759 (1997-07-01), Pfreundschuh
patent: 5866372 (1999-02-01), Stein et al.
patent: 6033876 (2000-03-01), Lemke et al.
patent: 6143869 (2000-11-01), Goodwin et al.
patent: 6632927 (2003-10-01), Adair et al.
patent: 2002/0064527 (2002-05-01), Mohler et al.
patent: 2005/0054055 (2005-03-01), Kucherlapati et al.
patent: 657533 (1995-06-01), None
patent: 613497 (1997-07-01), None
patent: 805871 (1999-11-01), None
patent: WO 91/07437 (1991-05-01), None
patent: WO 91/07941 (1991-06-01), None
patent: WO 92/03918 (1992-03-01), None
patent: WO 93/10232 (1993-05-01), None
patent: WO 94/04189 (1994-03-01), None
patent: WO 94/25585 (1994-11-01), None
patent: WO 96/22384 (1996-06-01), None
patent: WO 97/17374 (1997-05-01), None
patent: WO 98/24884 (1998-06-01), None
patent: WO 99/40187 (1999-08-01), None
patent: WO 01/11059 (2001-02-01), None
patent: WO 02/11767 (2002-02-01), None
patent: WO 02/17979 (2002-03-01), None
patent: WO 02/17979 (2002-03-01), None
patent: WO 02/43661 (2002-06-01), None
Rudikoff et al Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci U S A. Mar. 1982;79(6):1979-83.
Panka et al. Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies. Proc Natl Acad Sci U S A. 85(9):3080-3084, 1988.
Andreesen, R., et al. “A Hodgkin cell-specific antigen is expressed on a subset of auto- and alloactivated T (helper) lymphoblasts”BloodJun. 1984; 63(6):1299-302.
Barth, S., et al. “Ki-4(scFv)-ETA′, a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice”BloodJun. 15, 2000;95(12):3909-14.
Bowen, M., et al. “Functional effects of CD30 on a large granular lymphoma cell line, YT. Inhibition of cytotoxicity, regulation of CD28 and IL-2R, and induction of homotypic aggregation”J Immunol.Dec. 1, 1993;151(11):5896-906.
Burns, B., et al. “Ki-1-positive non-Hodgkin's lymphomas. An immunophenotypic, ultrastructural, and morphometric study”Am J Clin Pathol.Mar. 1990;93(3):327-32.
Carde, P., et al. “Immunoscintigraphy of Hodgkin's disease: In vivo use of radiolabelled monoclonal antibodies derived from Hodgkin cell lines”Eur J Cancer.Apr. 1990;26(4):474-9.
Chiarle, R., et al. “CD30 in normal and neoplastic cells”Clin Immunol.Feb. 1999;90(2):157-64.
de Bruin, P.C., et al. “CD30 expression in normal and neoplastic lymphoid tissue: biological aspects and clinical implications”LeukemiaOct. 1995;9(10):1620-7.
Durkop, H., et al. “Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease”CellFeb. 7, 1992;68(3):421-7.
Eckert, F., et al. “Follicular lymphoid hyperplasia of the skin with high content of Ki-1 positive lymphocytes”Am J Dermatopathol.Aug. 1989;11(4):345-52.
Engert, A., et al. “Treatment of advanced Hodgkin's lymphoma: standard and experimental approaches”Semin Hematol.Jul. 1999;36(3):282-9.
Engert, A., et al. “Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease”Cancer Res.Jan. 1, 1990;50(1):84-8.
Engert, A., et al. “Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice”Cancer Res.May 15, 1990;50(10):2929-35.
Falini, B., et al. “In vivo targeting of Hodgkin and Reed-Sternberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30): immunohistological evidence”Br J Haematol.Sep. 1992;82(1):38-45.
Falini, B., et al. “Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotixin”LancetMay 16, 1992;339(8803):1195-6.
Froese, P., et al. “Biochemical characterization and biosynthesis of the Ki-1 antigen in Hodgkin-derived and virus-transformed human B and T lymphoid cell lines”J Immunol.Sep. 15, 1987;139(6):2081-7.
Gruss, H.J. et al. “Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines”BloodApr. 15, 1994;83(8):2045-56.
Hecht, T., et al. “Production and characterization of a monoclonal antibody that binds Reed-Sternberg cells”J Immunol.Jun. 1985;134(6):4231-6.
Horn-Lohrens, O., et al. “Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4)”Int J Cancer.Feb. 8, 1995;60(4):539-44.
Hsu, S.M., et al. “Effect of monoclonal antibodies anti-2H9, anti-IRac, and anti-HeFi-1 on the surface antigens of Reed-Sternberg cells”J Natl Cancer Inst.Nov. 1987;79(5):1091-9.
Hubinger, G., et al. “CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299”Oncogene.Feb. 1, 2001;20(5):590-8.
Josimovic-Alasevic, O., et al. “Ki-1 (CD30) antigen is released by Ki-1 positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay”Eur J Immunol.Jan. 1989;19(1):157-62.
May, R. D., et al. “Evaluation of ricin A chain-containing immunotoxins directed against different epitopes on the delat-chain of cell surface-associated IgD on murine B cells”J Immunol.May 1, 1990;144(9):3637-42.
Mechtersheimer, G., et al. “Expression of Ki-1 antigen (CD30) in mesenchymal tumors”CancerOct. 15, 1990;66(8):1732-7.
Miettinen, M., “CD30 distribution. Immunohistochemical study on formaldehyde-fixed, paraffin-embedded Hodgkin's and non-Hodgkin's lymphomas”Arch Pathol Lab Med.Nov. 1992;116(11):1197-201.
Pallesen, G., et al. “The diagnostic significance of the CD30 (Ki-1) antigen”HistopathologyApr. 1990;16(4):409-13.
Pallesen, G., et al. “Ki-1 (CD30) antigen is regularly expressed by tumor cells of embryonal carcinoma”Am J Pathol.Dec. 1988;133(3):446-50.
Piris, M., et al. “CD30 expression in non-Hodgkin's lymphoma”HistopathologySep. 1990;17(3):211-8.
Pfreundschuh, M., et al. “Hodgkin and Reed-Sternberg cell associated monoclonal antibodies HRS-1 and HRS-2 react with activated cells of lymphoid and monocytoid origin”Anticancer Res.Mar.-Apr. 1988;8(2):217-24.
Pohl, C., et al. “CD30-specific AB1-AB2-AB3 internal image antibody network: potential use as anti-idiotype vaccine against Hodgkin's lymphoma”Int. J. CancerMay 28, 1993;54(3):418-25.
Press, O.W., et al. “Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells”J. Immunol.Dec. 15, 1988;141(12):4410-7.
Schwab, U., “Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells”NatureSep. 2, 1982;299(5878):65-7.
Schwarting, R., et al. “BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope”BloodOct. 1989;74(5):1678-89.
Stein, H., et al. “The expression of the Hodgkin'
Deo Yashwant M.
Graziano Robert
Keler Tibor
Treml John
Haddad Maher M.
Lahive & Cockfield LLP
Medarex Inc.
Remillard, Esq. Jane E.
LandOfFree
Human monoclonal antibodies against CD30 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human monoclonal antibodies against CD30, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human monoclonal antibodies against CD30 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2800428